A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer

Introduction Radium-223 (Xofigo, Bayer Pharmaceuticals Inc., Whippany, NJ) has been shown to increase overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), via the phase 3 ALpharadin in SYMPtomatic Prostate CAncer (ASLYMPCA) study. Hematologic side effects of rad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cureus
Main Authors: Skelton, William P, Dibenedetto, Samantha W, Pang, Shiyi S, Pan, Kelsey, Barish, Jacob L, Nwosu-Iheme, Adaeze, Dang, Long
Formato: Artigo
Idioma:Inglês
Publicado em: Cureus 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7047342/
https://ncbi.nlm.nih.gov/pubmed/32140364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.6806
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados